Vijay Pande

Background

Vijay Satyanand Pande is a Trinidadian-American scientist and venture capitalist ¹. He holds a BA in Physics from Princeton University and a PhD in Physics from MIT ¹. As a high school student at Langley High School in McLean, Virginia, he was awarded fourth place in the 1988 Westinghouse Science Talent Search ¹.

In his teens, Pande was the first employee at video game startup Naughty Dog, the studio behind Crash Bandicoot and The Last of Us ¹.

Before entering venture capital, Pande was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University, where he also directed the Biophysics program ¹². He is best known for creating Folding@home, a distributed computing protein-folding research project that earned a Guinness World Record and pioneered applications of distributed computing, machine learning, and novel computer architectures to biology and medicine ¹². He also co-founded Globavir Biosciences, focused on Dengue Fever and Ebola research ².

In 2015, Pande became the ninth general partner at Andreessen Horowitz (a16z), where he founded the firm’s Bio + Health Fund ¹³. The fund invested in life sciences and healthcare through four dedicated funds with more than $3 billion under management, including a $1.5 billion fund raised in 2022 ¹³⁴.

In December 2024, Pande stepped down from his leadership role at a16z Bio + Health ⁴. He subsequently announced he was “stepping away from my role at Andreessen Horowitz” after more than a decade, describing it as “one of the most meaningful chapters of my life” ⁵. In October 2025, Pande co-founded VZVC with Zack Werner, a new venture firm focused on AI-enabled healthcare, which is raising its first fund of up to $400 million ⁶.

Pande also serves as a Scientific Advisor to insitro ⁷.

Stated Thesis

(Self-reported: These represent what Pande says publicly about his approach. See Inferred Thesis for analysis of actual investment behavior.)

Pande’s stated thesis centers on the idea that biology is transitioning from an empirical science to an engineering discipline. He has described this shift as moving “from having artisanal people like craftsmans making something to something that’s done in a very systematic way” ⁸.

Pande has stated that he convinced Andreessen Horowitz’s co-founders in 2014 “that there was a major inflection point, and that tech is really changing how life science is done” ⁸. He leads investments “at the cross section of biology and computer science, including applications in computation, machine learning, and artificial intelligence in healthcare” ².

On AI in drug design, Pande has stated: “Where we stand today is that AI and drug design is, I think, no longer a question of if, it’s a question of how, how does it get rolled out?” ⁸

On democratizing medicine through AI, Pande has noted that when AI can be trained from the very best doctors, “it can give access effectively of the very best doctors to everyone, and that democratization of medicine would be very exciting” ⁸.

In his Substack departure announcement, Pande credited his success to recognizing that “tech companies are poised to make major impacts in Bio and Health” ⁵.

Inferred Thesis

Based on 14 verified investments in the portfolio table below:

Stage distribution: Pande invests primarily at early stages. Of 14 verified investments, the majority are Series A or Series B rounds, consistent with a16z Bio + Health’s positioning as an early-stage biotech and health investor.

Sector concentration (of 14 verified investments): - Therapeutics / drug discovery: 5 companies (36%) — Scribe Therapeutics, Genesis Therapeutics, BioAge Labs, Inceptive Therapeutics, Alpine Bio - Digital health / health platforms: 4 companies (29%) — Devoted Health, Omada Health, Function Health, Q.bio - Computational biology / AI-bio: 2 companies (14%) — insitro, Nautilus Biotechnology - Food / agriculture tech: 1 company (7%) — Apeel Sciences - Diagnostics: 1 company (7%) — Freenome - Consumer health data: 1 company (7%) — Ciitizen

Key patterns:

Biology-as-engineering thesis is genuine: Pande’s portfolio overwhelmingly reflects companies applying computational, engineering, or AI approaches to biology — insitro (ML for drug discovery), Scribe Therapeutics (engineered CRISPR), Freenome (AI-based cancer diagnostics), Genesis Therapeutics (AI for drug design). This is one of the rarer cases where stated thesis and portfolio behavior are tightly aligned.

Health insurance and delivery: Devoted Health (health insurance) and Omada Health (digital chronic disease management) represent a significant sub-thesis around healthcare delivery and prevention — not just drug discovery. This broader “health system redesign” angle is less emphasized in Pande’s public communications.

Board-heavy involvement: Pande sits or sat on the boards of nearly all his investments (13 of 14 verified), suggesting a deeply hands-on approach. This is consistent with his academic background — he appears to function as a technical advisor as much as a financial investor.

Co-investor patterns: As a16z Bio + Health GP, Pande frequently co-invested with other specialized biotech investors including ARCH Venture Partners, GV (Google Ventures), and Flagship Pioneering.

Founder profile: Pande’s portfolio leans heavily toward scientific founders — PhD founders and researchers transitioning from academia to startups, particularly from Stanford, MIT, and UC Berkeley.

Notable gaps: Despite a16z’s broader interest in consumer tech, Pande’s portfolio has minimal consumer exposure. Apeel Sciences (food preservation) is the closest to a consumer play. His investments are concentrated in the Bay Area biotech ecosystem with limited geographic diversity.

Portfolio

Note: Several investment years are approximate, based on board appointment dates and fund timelines. Pande has likely led or participated in additional investments through the a16z Bio + Health fund that are not individually attributed to him.

In Their Own Words

“Where we stand today is that AI and drug design is, I think, no longer a question of if, it’s a question of how, how does it get rolled out?” — Vijay Pande, GEN Edge interview, 2023 ⁸

“Tech companies are poised to make major impacts in Bio and Health.” — Vijay Pande, Substack, 2025 ⁵

“Stepping away from my role at Andreessen Horowitz… one of the most meaningful chapters of my life.” — Vijay Pande, Substack, 2025 ⁵

On Scribe Therapeutics: Pande wrote that the company takes an engineering-focused approach to CRISPR gene editing, moving “beyond natural CRISPR discovery toward designing improved therapeutic molecules with enhanced efficacy, specificity, delivery, and immune response properties” ¹⁰.

What Founders Say

No independently sourced founder testimonials found.

Sources